LiVeritas Biosciences
LiVeritas Biosciences, Inc. is a biopharmaceutical company focused on accelerating drug discovery and development through its Mass Spectrometry as a Service (MSaaS) offering. Their solution provides a streamlined LC-MS workflow, delivering results up to 100x faster than traditional methods without compromising accuracy. They address critical industry needs for efficient drug candidate identification, overcoming challenges with outdated testing processes, data compatibility, and extracting actionable insights. LiVeritas Biosciences offers tailored LC-MS services, leveraging a state-of-the-art laboratory and advanced instrumentation to deliver high-throughput, reproducible data with guaranteed timelines. Their expertise spans antibody-derived drug candidates, ADCs, gene and cell therapy, and analytical development strategy, aligning with CMC strategies and phase-appropriate project objectives. The company aims to be a trusted outsourcing partner for biopharma companies seeking transformative strategic MS analysis.
LiVeritas Biosciences
LiVeritas Biosciences, Inc. is a biopharmaceutical company focused on accelerating drug discovery and development through its Mass Spectrometry as a Service (MSaaS) offering. Their solution provides a streamlined LC-MS workflow, delivering results up to 100x faster than traditional methods without compromising accuracy. They address critical industry needs for efficient drug candidate identification, overcoming challenges with outdated testing processes, data compatibility, and extracting actionable insights. LiVeritas Biosciences offers tailored LC-MS services, leveraging a state-of-the-art laboratory and advanced instrumentation to deliver high-throughput, reproducible data with guaranteed timelines. Their expertise spans antibody-derived drug candidates, ADCs, gene and cell therapy, and analytical development strategy, aligning with CMC strategies and phase-appropriate project objectives. The company aims to be a trusted outsourcing partner for biopharma companies seeking transformative strategic MS analysis.